Data Integrity: COVID-19 Impacted Studies Pose Unique Enforcement Risks
Executive Summary
Move toward decentralized trials means sponsors may be working with naïve clinical investigators who lack experience, Greenleaf’s Cynthia Schnedar says; DoJ’s Gustav Eyler urges drug sponsors to look for oddities in clinical trial data and to voluntarily report potential misconduct.
You may also be interested in...
Theranos Cases Show How DoJ Looks Beyond The FDCA In Prosecuting Drug, Device Companies
Charges under wire fraud statute carry higher maximum prison sentences and are easier to explain than FDCA misbranding charges, Department of Justice officials say in dissecting the guilty verdicts and lengthy prison sentences for former leaders of the failed blood testing start-up.
Theranos Cases Show How DoJ Looks Beyond The FDCA In Prosecuting Drug, Device Companies
Charges under wire fraud statute carry higher maximum prison sentences and are easier to explain than FDCA misbranding charges, Department of Justice officials say in dissecting the guilty verdicts and lengthy prison sentences for former leaders of the failed blood testing start-up.
Theranos Cases Show How DoJ Looks Beyond The FDCA In Prosecuting Drug, Device Companies
Charges under wire fraud statute carry higher maximum prison sentences and are easier to explain than FDCA misbranding charges, Department of Justice officials say in dissecting the guilty verdicts and lengthy prison sentences for former leaders of the failed blood testing start-up.